A human or humanized monoclonal IgG antibody (mAb) specifically recognizing the D-galactan-II antigen of Klebsiella pneumoniae O1 which is characterized by a bactericidal CDC activity, its method of production, medical and diagnostic use.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae , which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

##STR00001##

The invention relates to methods of screening biological samples from a subject for the presence of one or more microorganisms, such as the presence in the subject of one or more pathogenic or potentially pathogenic microorganisms, and diagnostic kits and devices suitable for carrying out said methods. More particularly, the present invention relates to sensitive and specific methods for determining the presence of gram-negative bacteria or analytes therefrom in a sample from a subject using immunoassays, and devices and kits for carrying out such methods.

Methods and systems for rapid prediction and/or confirmation of antimicrobial susceptibility of a microorganism using top-down mass spectrometry, ion-ion chemistry, and a database with susceptibility, pathogenicity and antimicrobial resistance markers for sample characterization.

The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.

The present invention relates to a composition for preventing, alleviating or treating liver injury, for example, nonalcoholic fatty liver, and more specifically, it relates to a composition for preventing or treating liver injury comprising a Ruminococcus spp. strain.

Provided are a single-stranded nucleic acid aptamer simultaneously and specifically binding to various types of microorganisms, and a method of manufacturing the nucleic acid aptamer. For example, provided are a probe that is capable of simultaneously detecting or diagnosing a variety of microorganisms, and a method of manufacturing an aptamer having characteristics of such a probe.

The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.